» Articles » PMID: 24952078

Is the Outcome of a Salvage Surgery for T4 Thoracic Esophageal Squamous Cell Carcinoma Really Poor?

Overview
Journal World J Surg
Publisher Wiley
Specialty General Surgery
Date 2014 Jun 22
PMID 24952078
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Among patients with T4 thoracic esophageal squamous cell carcinoma (TESCC), it is unclear whether the outcomes of late responders who undergo high-dose chemoradiotherapy (CRT) followed by salvage esophagectomy differs from those of early responders who undergo low-dose CRT followed by esophagectomy.

Methods: A total of 153 patients with T4 TESCC were treated with CRT. The first evaluation was performed after 40 Gy of CRT for downstaging. Of these, 28 patients could be downstaged, and underwent subsequent surgery (early responders). For the remaining patients, additional CRT was administered, and patients were re-evaluated after treatment and underwent salvage surgery. In total, 40 patients (early + late responders) were analyzed.

Results: The primary tumors exhibited a grade 3 response in six (21.4 %) of the early responders and two (16.7 %) of the late responders (p = 1.000). The rate of residual tumor in the primary tumor was 80 % (32/40 patients). The proportions of resected lymph nodes and positive metastatic nodes were similar between early and late responders (p = 0.406 and p = 0.859, respectively). The 5-year overall survival rates among the early and late responders were 25.9 and 36.5 %, respectively, and the median survival times were 24.8 and 24.3 months (p = 0.925), respectively. The 5-year cause-specific survival rates in the early and late responder groups were 61.5 and 72.9 % (p = 0.425), respectively.

Conclusion: The outcomes of both early and late responders to CRT were similar, and salvage surgery for T4 TESCC outweighs the risks in patients with T4 TESCC.

Citing Articles

Role of surgery in T4N0-3M0 esophageal cancer.

Qi C, Hu L, Zhang C, Wang K, Qiu B, Yi J World J Surg Oncol. 2023; 21(1):369.

PMID: 38008742 PMC: 10680323. DOI: 10.1186/s12957-023-03239-8.


Chemoradiotherapy versus triplet chemotherapy as initial therapy for T4b esophageal cancer: survival results from a multicenter randomized Phase 2 trial.

Yamasaki M, Miyata H, Yamashita K, Hamakawa T, Tanaka K, Sugimura K Br J Cancer. 2023; 129(1):54-60.

PMID: 37142731 PMC: 10307786. DOI: 10.1038/s41416-023-02286-y.


Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1.

Kitagawa Y, Ishihara R, Ishikawa H, Ito Y, Oyama T, Oyama T Esophagus. 2023; 20(3):343-372.

PMID: 36933136 PMC: 10024303. DOI: 10.1007/s10388-023-00993-2.


Multimodal Treatment Strategies to Improve the Prognosis of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: A Narrative Review.

Higuchi T, Shoji Y, Koyanagi K, Tajima K, Kanamori K, Ogimi M Cancers (Basel). 2023; 15(1).

PMID: 36612007 PMC: 9817845. DOI: 10.3390/cancers15010010.


Long-term outcomes of multimodal therapy combining definitive chemoradiotherapy and salvage surgery for T4 esophageal squamous cell carcinoma.

Sugawara K, Yagi K, Okumura Y, Nishida M, Aikou S, Yamashita H Int J Clin Oncol. 2019; 25(4):552-560.

PMID: 31828451 DOI: 10.1007/s10147-019-01590-z.


References
1.
Shimoji H, Karimata H, Nagahama M, Nishimaki T . Induction chemotherapy or chemoradiotherapy followed by radical esophagectomy for T4 esophageal cancer: results of a prospective cohort study. World J Surg. 2013; 37(9):2180-8. DOI: 10.1007/s00268-013-2074-x. View

2.
Akutsu Y, Matsubara H, Shuto K, Uesato M, Mori M, Hoshino I . Clinical and pathologic evaluation of the effectiveness of neoadjuvant chemoradiation therapy in advanced esophageal cancer patients. World J Surg. 2009; 33(5):1002-9. DOI: 10.1007/s00268-008-9899-8. View

3.
Akutsu Y, Uesato M, Shuto K, Kono T, Hoshino I, Horibe D . The overall prevalence of metastasis in T1 esophageal squamous cell carcinoma: a retrospective analysis of 295 patients. Ann Surg. 2012; 257(6):1032-8. DOI: 10.1097/SLA.0b013e31827017fc. View

4.
Akutsu Y, Shuto K, Kono T, Uesato M, Hoshino I, Shiratori T . The number of pathologic lymph nodes involved is still a significant prognostic factor even after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma. J Surg Oncol. 2011; 105(8):756-60. DOI: 10.1002/jso.23007. View

5.
Nabeya Y, Ochiai T, Matsubara H, Okazumi S, Shiratori T, Shuto K . Neoadjuvant chemoradiotherapy followed by esophagectomy for initially resectable squamous cell carcinoma of the esophagus with multiple lymph node metastasis. Dis Esophagus. 2005; 18(6):388-97. DOI: 10.1111/j.1442-2050.2005.00521.x. View